AR042670A1 - Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal - Google Patents
Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominalInfo
- Publication number
- AR042670A1 AR042670A1 ARP030104848A ARP030104848A AR042670A1 AR 042670 A1 AR042670 A1 AR 042670A1 AR P030104848 A ARP030104848 A AR P030104848A AR P030104848 A ARP030104848 A AR P030104848A AR 042670 A1 AR042670 A1 AR 042670A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- group
- halogen
- heterocyclic
- chloride channel
- Prior art date
Links
- 108010062745 Chloride Channels Proteins 0.000 title abstract 3
- 102000011045 Chloride Channels Human genes 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003187 abdominal effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- -1 prostaglandin compound Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 206010000059 abdominal discomfort Diseases 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43646202P | 2002-12-27 | 2002-12-27 | |
| US43646302P | 2002-12-27 | 2002-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042670A1 true AR042670A1 (es) | 2005-06-29 |
Family
ID=32717850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104848A AR042670A1 (es) | 2002-12-27 | 2003-12-29 | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7795312B2 (https=) |
| EP (2) | EP1575596B1 (https=) |
| JP (2) | JP4889219B2 (https=) |
| KR (2) | KR101164838B1 (https=) |
| CN (1) | CN1753680B (https=) |
| AR (1) | AR042670A1 (https=) |
| AU (1) | AU2003292556B2 (https=) |
| BR (1) | BRPI0317740B8 (https=) |
| CA (1) | CA2510051C (https=) |
| ES (1) | ES2591252T3 (https=) |
| MX (1) | MXPA05006981A (https=) |
| NO (1) | NO335441B1 (https=) |
| NZ (1) | NZ541110A (https=) |
| TW (1) | TWI336254B (https=) |
| WO (1) | WO2004060377A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR037524A1 (es) | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| DK1562604T3 (da) * | 2002-10-23 | 2012-04-02 | Sucampo Ag | Prostaglandinforbindelser til behandling af fedme |
| ATE489096T1 (de) * | 2003-07-03 | 2010-12-15 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
| TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| WO2006109881A1 (en) * | 2005-04-12 | 2006-10-19 | Sucampo Ag | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
| US7868045B2 (en) | 2006-09-06 | 2011-01-11 | Sucampo Ag | Method for promoting gastrointestinal bicarbonate secretion |
| EP2114411A2 (en) * | 2007-02-27 | 2009-11-11 | Sucampo AG | Composition and method for protecting mitochondria |
| US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| US20090030072A1 (en) * | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
| CA2774021A1 (en) * | 2009-09-18 | 2011-03-24 | Adolor Corporation | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| IT1402047B1 (it) * | 2010-10-19 | 2013-08-28 | Cross Pharma Sa | Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| JP2015514681A (ja) * | 2012-04-23 | 2015-05-21 | スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ | 下痢を伴う過敏性腸症候群の処置方法 |
| PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1581886A (en) * | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
| US5317032A (en) * | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| TW224942B (https=) | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| JP3187438B2 (ja) | 1996-06-10 | 2001-07-11 | 株式会社アールテック・ウエノ | エンドセリン拮抗剤 |
| US6046239A (en) * | 1997-08-05 | 2000-04-04 | American Home Products Corporation | Anthranilic acid analogs |
| ES2310013T3 (es) * | 1997-11-28 | 2008-12-16 | Sucampo Ag | Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina. |
| US6492417B1 (en) * | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
| RU2695274C3 (ru) * | 1999-10-15 | 2020-11-09 | Сукампо Аг | Новые композиции и способы их стабилизации |
| NZ521784A (en) * | 2000-04-06 | 2005-04-29 | Sucampo Ag | Bile secretion promoting composition |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| WO2002094274A1 (en) * | 2001-05-18 | 2002-11-28 | Sucampo Ag | Cathartic composition |
| EP1420794B1 (en) | 2001-08-31 | 2017-12-27 | Sucampo AG | Prostaglandin analogs as chloride channel openers |
| AR037524A1 (es) * | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| TWI263505B (en) * | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
-
2003
- 2003-12-26 BR BRPI0317740A patent/BRPI0317740B8/pt not_active IP Right Cessation
- 2003-12-26 KR KR1020057012162A patent/KR101164838B1/ko not_active Expired - Lifetime
- 2003-12-26 ES ES03768289.5T patent/ES2591252T3/es not_active Expired - Lifetime
- 2003-12-26 EP EP03768289.5A patent/EP1575596B1/en not_active Expired - Lifetime
- 2003-12-26 MX MXPA05006981A patent/MXPA05006981A/es active IP Right Grant
- 2003-12-26 NZ NZ541110A patent/NZ541110A/en not_active IP Right Cessation
- 2003-12-26 WO PCT/JP2003/016857 patent/WO2004060377A1/en not_active Ceased
- 2003-12-26 JP JP2004564537A patent/JP4889219B2/ja not_active Expired - Lifetime
- 2003-12-26 CA CA2510051A patent/CA2510051C/en not_active Expired - Lifetime
- 2003-12-26 CN CN2003801099014A patent/CN1753680B/zh not_active Expired - Lifetime
- 2003-12-26 AU AU2003292556A patent/AU2003292556B2/en not_active Expired
- 2003-12-26 TW TW092136988A patent/TWI336254B/zh not_active IP Right Cessation
- 2003-12-26 KR KR1020127006692A patent/KR20120045051A/ko not_active Ceased
- 2003-12-26 EP EP10177588A patent/EP2281564A3/en not_active Withdrawn
- 2003-12-29 US US10/745,689 patent/US7795312B2/en not_active Expired - Lifetime
- 2003-12-29 AR ARP030104848A patent/AR042670A1/es not_active Application Discontinuation
-
2005
- 2005-07-26 NO NO20053623A patent/NO335441B1/no not_active IP Right Cessation
-
2010
- 2010-08-02 US US12/848,597 patent/US20100298424A1/en not_active Abandoned
-
2011
- 2011-11-01 JP JP2011240314A patent/JP2012031202A/ja active Pending
-
2013
- 2013-03-18 US US13/845,353 patent/US20130217770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1753680A (zh) | 2006-03-29 |
| NO335441B1 (no) | 2014-12-15 |
| US20100298424A1 (en) | 2010-11-25 |
| EP1575596A1 (en) | 2005-09-21 |
| MXPA05006981A (es) | 2005-12-14 |
| NZ541110A (en) | 2008-11-28 |
| BR0317740A (pt) | 2005-11-22 |
| US20130217770A1 (en) | 2013-08-22 |
| EP2281564A2 (en) | 2011-02-09 |
| TW200418491A (en) | 2004-10-01 |
| WO2004060377A1 (en) | 2004-07-22 |
| NO20053623D0 (no) | 2005-07-26 |
| TWI336254B (en) | 2011-01-21 |
| CN1753680B (zh) | 2010-12-08 |
| AU2003292556B2 (en) | 2009-09-10 |
| EP1575596B1 (en) | 2016-06-22 |
| JP2006513232A (ja) | 2006-04-20 |
| KR20050086950A (ko) | 2005-08-30 |
| US20040138308A1 (en) | 2004-07-15 |
| KR101164838B1 (ko) | 2012-07-11 |
| NO20053623L (no) | 2005-09-26 |
| ES2591252T3 (es) | 2016-11-25 |
| JP4889219B2 (ja) | 2012-03-07 |
| BRPI0317740B8 (pt) | 2021-05-25 |
| EP2281564A3 (en) | 2012-09-05 |
| JP2012031202A (ja) | 2012-02-16 |
| US7795312B2 (en) | 2010-09-14 |
| KR20120045051A (ko) | 2012-05-08 |
| AU2003292556A1 (en) | 2004-07-29 |
| BRPI0317740B1 (pt) | 2018-09-18 |
| CA2510051C (en) | 2016-07-05 |
| CA2510051A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042670A1 (es) | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal | |
| AR100696A2 (es) | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas | |
| AR036391A1 (es) | Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| CL2020000029A1 (es) | Nuevos compuestos de carboxamida sulfonamida. | |
| CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
| CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
| AR073158A1 (es) | Metodo y composicion para modular el crecimiento de celulas madre | |
| CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
| ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| CL2021001039A1 (es) | Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
| CO5031247A1 (es) | Compuestos triciclicos sustituidos | |
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares | |
| CO5550437A2 (es) | Compuestos quimicos | |
| AR111272A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| DE60121587D1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |